Latest Headlines
-
BioCentriq Selected To Present Its Capabilities At Meeting On The Mesa
8/2/2023
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference that addresses the commercialization challenges of today’s cell and gene therapy industry.
-
New Cell Therapy CDMO Kincell Bio To Develop In-House Manufacturing Capacity
7/26/2023
Kincell Bio, a technology-forward contract development and manufacturing organization (CDMO) focused on cell therapies, today emerged from stealth with $36 million in new funding. Kineticos Ventures led Kincell’s launch funding.
-
CDMO Biovian Announces Significant Investment Into Drug Manufacturing Facility In Finland
7/26/2023
Biovian Oy, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, announces a major investment of over €50 million to expand its manufacturing facility in Turku, Finland.
-
Qosina Introduces Aramus™ 2D Bag Chambers From Entegris To Its Bioprocess Components Portfolio
7/20/2023
Qosina is pleased to announce the addition of Aramus 2D bag chambers from Entegris.
-
Entegris And Agilitech: Transforming Single-Use Technologies
7/19/2023
Entegris announces their collaboration with Agilitech, allowing them to offer an extended line of custom, single-use systems for cell and gene therapies.
-
Fujifilm Appoints Lars Petersen As President & CEO Of FUJIFILM Diosynth Biotechnologies, Leading Global Bio CDMO
6/29/2023
Petersen succeeds Martin Meeson who has served as FUJIFILM Diosynth Biotechnologies president and CEO since 2020.
-
Project Farma And Precision For Medicine Acquire Baseline Controls
6/27/2023
Precision for Medicine, the first global biomarker-driven clinical research and development organization, today announced that it has acquired Baseline Controls, a Raleigh, North Carolina-based company that provides dedicated engineers with specialized expertise in project feasibility, execution planning, and baseline performance management. Baseline Control’s expertise will become part of Project Farma, Precision for Medicine’s existing biomanufacturing strategy and execution group, expanding the scope of its manufacturing solutions for life science companies and driving greater speed and efficiency in bringing new drugs to market.
-
NIIMBL Funding Helps To Accelerate Bringing Gene Therapies To Market
6/27/2023
New funding from NIIMBL was announced to develop a viral and exotoxin clearance platform for AAV manufacturing. The goal of this project is to establish new standards and advance gene therapies.
-
Precision NanoSystems And Aurora Vaccines Join Forces To Accelerate The Development Of Vaccine Candidate For Hepatitis C Virus
6/23/2023
Global leader in non-viral delivery of genomic medicines, Precision NanoSystems (PNI), entered into a strategic collaboration agreement with Aurora Vaccines to accelerate the development and manufacture of its Hepatitis C vaccine candidate. PNI will share its expertise in the development of the RNA payload platform and its proprietary lipid nanoparticle (LNP) platforms to help bring Aurora’s RNA-LNP vaccine candidate for the prevention of Hepatitis C virus (HCV) infection to a Phase I clinical trial.
-
Novotech Selected For Biotech CRO Leadership Award 2023
6/21/2023
Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities has been selected for the prestigious CRO Leadership Award 2023 for exceeding biotech customer expectations in the “Compatibility” category.